How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,340 results for

Sentinel Node Breast Biopsy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy

Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy Axillary radiotherapy - Health Technology Wales > Axillary radiotherapy Axillary radiotherapy Topic Status Complete Whole breast irradiation with supraclavicular fossa radiotherapy and axillary radiotherapy for people with early breast cancer following a macrometastatic sentinel node biopsy. Summary This report

2019 Health Technology Wales

2. Internal Mammary Sentinel Lymph Node Biopsy in Clinically Axillary Lymph Node-Positive Breast Cancer: Diagnosis and Implications for Patient Management. Full Text available with Trip Pro

Internal Mammary Sentinel Lymph Node Biopsy in Clinically Axillary Lymph Node-Positive Breast Cancer: Diagnosis and Implications for Patient Management. Routine performance of internal mammary sentinel lymph node biopsy (IM-SLNB) remains a subject of debate due to no clinical relevance in breast cancer, because it was performed only in clinically axillary lymph node (ALN)-negative patients. In this study, IM-SLNB was performed in clinically ALN-positive patients, and its impact on nodal staging (...) and therapeutic strategy were subsequently analyzed.Clinically ALN-positive patients who underwent IM-SLNB were enrolled in this prospective study. Statistical analysis was performed using Chi square test, Mann-Whitney U and logistic regression models with a significance level of 0.05.Among the 352 recruited patients, the internal mammary sentinel lymph node (IMSLN) visualization rate of patients who received initial surgery and neoadjuvant systemic therapy (NST) was 71.9% (123/171) and 33.1% (60/181

2019 Annals of Surgical Oncology

3. Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines

Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines | CADTH.ca Find the information you need Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Sentinel Lymph Node Biopsy for the Management of Breast Cancer: A Review of Guidelines Last updated: April 24, 2019 Project Number: RC1103-000 Product Line: Research Type: Devices and Systems (...) Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines regarding methods for sentinel lymph node biopsy for the management of breast cancer? Key Message Five evidence-based guidelines were identified. SLNB is recommended for axillary staging for patients with early-stage or invasive breast cancer without clinically or pathologically positive lymph nodes. SLNB is recommended in patients with ductal carcinoma in situ (DCIS) when mastectomy

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Axillary Lymph Node Dissection for Clinical Stage I and II Breast Cancer with Clinically Negative Lymph Nodes without Attempting Sentinel Node Biopsy

Axillary Lymph Node Dissection for Clinical Stage I and II Breast Cancer with Clinically Negative Lymph Nodes without Attempting Sentinel Node Biopsy Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all (...) and conditions. TITLE: Axillary Lymph Node Dissection for Clinical Stage I and II Breast Cancer with Clinically Negative Lymph Nodes without Attempting Sentinel Node Biopsy: Clinical Effectiveness and Guidelines DATE: 31 March 2015 RESEARCH QUESTIONS 1. What is the clinical effectiveness of axillary lymph node dissection for clinical stages I and II breast cancer with clinically negative lymph nodes without attempting sentinel node biopsy? 2. What are the evidence-based guidelines regarding axillary lymph

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial (Abstract)

Prospective, Multicenter, Randomized Phase III Trial Evaluating the Impact of Lymphoscintigraphy as Part of Sentinel Node Biopsy in Early Breast Cancer: SenSzi (GBG80) Trial The aim of the current work was to clarify whether a preoperative lymphoscintigraphy (LSG) enhances staging accuracy of sentinel lymph node biopsy (SLNB).In a prospective, multicenter, randomized phase III trial, patients with cN0 early breast cancer or extensive/high-grade ductal carcinoma in situ planned for standard (...) radioactive-labeled colloid LSG with subsequent SLNB were randomly assigned 1:1 to receive SLNB either with knowledge of the LSG findings or without. As the false-negative rate of SLNB correlates with the number of resected sentinel lymph nodes (SLNs), our primary end point was the mean number of histologically detected SLNs per patient. One thousand one hundred two evaluable patients were necessary to demonstrate noninferiority of SLNB without LSG. Stratified one-sided 95% CI for the difference (without

2019 EvidenceUpdates

7. Nomograms for predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy. Full Text available with Trip Pro

Nomograms for predicting the likelihood of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy. Breast cancer patients with sentinel lymph node (SLN) metastases may have a low risk of non-SLN metastases. Accurate estimates of the likelihood of additional disease in the non-SLN metastases can avoid many complications mentioned the axillary lymph node dissection (ALND). This study aims to develop a new model based on Chinese real-world patients (...) to ascertain the likelihood of non-SLN metastases in a breast cancer patient with disease-positive SLN, enabling the surgeons to make a better choice of surgical procedures.Out of the 470 patients from CSCO Breast Cancer Database collaborated Group, a proportion of 3 (347 cases): 1 (123 cases) was considered for assigning patients to training and validation groups, respectively. Two training models were created to predict the likelihood of having additional, non-SLN metastases in an individual patient

2019 Medicine

8. Biological Subtypes of Breast Cancer and Sentinel Lymph Node Biopsy Full Text available with Trip Pro

Biological Subtypes of Breast Cancer and Sentinel Lymph Node Biopsy Breast cancer subtypes are used as prognostic and predictive factors considering the genomic profile of the disease. This study is designed to investigate the Sentinel Lymph Node (SLN) detection rate in breast cancer for different biological characteristics.Patients on whom we performed the methylene blue method alone were named as Group I, radiocolloid substance method alone as Group II and both methylene blue and radiocolloid (...) method as Group III. The results of biological tumor characteristics and characteristics of the patients on different SLN biopsy techniques were investigated.The overall SLN detecting success rate was 83.3%. When considered for each group, success rate was 80% for group I, 84.9% for group II and 90.6% for group III. While a success rate of 94.6% was achieved with radiocolloid only in the patients in Luminal A and B subgroup, 90% success rate was achieved in Her2 (+) and triple negative (TN) patients

2018 European journal of breast health

9. Internal Mammary Chain Sentinel Nodes in Early-Stage Breast Cancer Patients: Toward Selective Removal. (Abstract)

Internal Mammary Chain Sentinel Nodes in Early-Stage Breast Cancer Patients: Toward Selective Removal. Removal of internal mammary chain sentinel nodes (IMCSNs) affects prognosis and treatment of breast cancer, and internal mammary chain radiotherapy (IMCRT) can improve survival for selected patients. This study aimed to determine the effect of IMCSN biopsy on recurrence-free survival (RFS) and overall survival (OS) and to identify predictive factors for IMCSN and distant metastasis.Patients (...) with IMCSNs were selected from a prospective database for the period 1999-2007. Lymphoscintigraphy was performed after intratumoral technetium-99 m injection, and all sentinel nodes were removed. Both RFS and OS were calculated for subgroups with tumor-positive, tumor-negative, or non-removed IMCSNs. Predictive factors were identified for tumor-positive IMCSNs and distant metastasis by regression analysis.For 287 (85%) of 336 patients, IMCSN biopsy was performed, and metastasis was detected in 38 patients

2018 Annals of Surgical Oncology

10. Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique

Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique for Early Breast Cancer Estimated Study Start Date : July 1, 2018 Estimated Primary Completion Date : June 30, 2020 Estimated Study Completion Date : December 31, 2020 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: IM-SLNB with MIT The radiotracer was injected with our modified injection technique (MIT) (periareolar (...) Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Yongsheng Wang, Shandong Cancer Hospital and Institute: Breast Cancer Internal Mammary Lymph Node Internal Mammary Sentinel Lymph Node Biopsy Detection Rate Additional relevant MeSH terms: Layout table for MeSH terms Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases

2018 Clinical Trials

11. Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center. Full Text available with Trip Pro

Management of the axilla in patients with breast cancer and positive sentinel lymph node biopsy: An evidence-based update in a European breast center. The surgical approach to the axilla in breast cancer has been a controversial issue for more than three decades. Data from recently published trials have provided practice-changing recommendations in this scenario. However, further controversies have been triggered in the surgical community, resulting in heterogeneous diffusion (...) lymph node biopsy may be avoided in cN0 patients with micro/macrometastasis to ≤2 sentinel nodes, with age ≥40y, lesions ≤3 cm, who have not received neoadjuvant chemotherapy and have planned breast conservation (BCS) with whole breast radiotherapy (WBRT). Cases with gross (>2 mm) ECE in SLNs are evaluated on individual basis for completion ALND, axillary radiotherapy or omission of both. Patients fulfilling the criteria listed above who undergo mastectomy, may also avoid axillary dissection after

2019 European Journal of Surgical Oncology

12. Low-cost Fluorescein as an Alternative to Radio-colloid for Sentinel Lymph Node Biopsy-a Prospective Validation Study in Early Breast Cancer. (Abstract)

Low-cost Fluorescein as an Alternative to Radio-colloid for Sentinel Lymph Node Biopsy-a Prospective Validation Study in Early Breast Cancer. Sentinel lymph node biopsy (SLNB) using radio-pharmaceutical (RP) and a blue dye is gold standard for axillary staging in clinically node-negative early breast cancer. High costs and limited availability of RP and/or gamma probe are major deterrents in performing SLNB in developing countries. Fluorescence-guided SLNB can obviate the need for RP and gamma (...) probe. Fluorescein is an inexpensive fluorescent lymphatic tracer. In this study, we compared SLN identification rate (SLN-IR) and false negative rates (FNR) of fluorescein-guided SLNB and radio-guided SLNB using 99mTc-Sulfur-colloid, in isolation, or in combination with methylene blue dye (MBD).Sixty-five cN0 early and large operable breast cancer patients underwent validation SLNB using fluorescein (and blue LED light), 99mTc-Sulfur-colloid (and gamma probe) and MBD. Inj Fluorescein 4

2020 World Journal of Surgery

13. Sentinel lymph node biopsy for intermediate thickness melanoma

Sentinel lymph node biopsy for intermediate thickness melanoma 1 Public Summary Document Application No. 1485 – Sentinel Lymph Node Biopsy (SLNB) for intermediate thickness and thick melanoma Applicant: Australian Society of Specialist General Surgeons Date of MSAC consideration: MSAC 73 rd Meeting, 26-27 July 2018 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare Benefit (...) Schedule (MBS) listing for sentinel lymph node biopsy (SLNB) in patients with intermediate thickness (>1 to 4 mm) and thick (>4 mm) melanoma was received from Australian Society of Specialist General Surgeons by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost-effectiveness, MSAC deferred its advice on MBS funding for SLNB for intermediate thickness and thick cutaneous

2019 Medical Services Advisory Committee

14. Impact of sentinel lymph node biopsy in newly diagnosed invasive breast cancer patients with suspicious node: a comparative accuracy survey of fine-needle aspiration biopsy versus core-needle biopsy Full Text available with Trip Pro

Impact of sentinel lymph node biopsy in newly diagnosed invasive breast cancer patients with suspicious node: a comparative accuracy survey of fine-needle aspiration biopsy versus core-needle biopsy Comparing diagnostic accuracy study between ultrasonography (US) guided fine-needle aspiration biopsy (FNAB) and core-needle biopsy (CNB) of the Sentinel lymph nodes (SLNs) in newly diagnosed invasive breast cancer patients. We selected 289 newly diagnosed invasive breast cancer patients from June (...) 2015 to July 2017. Ultrasound (US) guided fine-needle aspiration cytology (FNA) and core-needle biopsy (CNB) was performed to identify patients with suspicious sentinel lymph node (SLN). Patients with a cortical thickness > 2 mm or atypical morphological characteristics were recommended FNA and CNB. Axillary lymph node dissection (ALND) was applied to patients with biopsy-proven metastasis, and sentinel lymph node biopsy (SLNB) was applied to FNA or CNB negative patients. ALND was also performed

2018 American journal of translational research

15. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. (Abstract)

Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Recent trials have demonstrated the feasibility of sentinel lymph node biopsy (SLNB) for cN1 breast cancer patients after neoadjuvant chemotherapy (NAC). This study evaluated the technical outcomes of SLNB by residual nodal disease volume.From a prospective database, cT1-3 cN1 patients receiving NAC and surgery from (...) %) and was not associated with nodal volume (p = 0.12). The FNR of the intraoperative SLN evaluation was 37.8%, and smaller nodal volume was associated with FNR (p < 0.01). Of 36 patients (37.5%) who achieved an axillary pathologic complete response, 24 (66.7%) had three or more negative SLNs and were safely spared axillary lymph node dissection (ALND). The positive predictive values of physical exam versus imaging-based post-NAC nodal assessment were respectively 88% and 69.8%.This study showed SLNB to be an effective

2019 Annals of Surgical Oncology

16. Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype. (Abstract)

Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype. The management of axilla after Primary Systemic Therapy (PST) for breast cancer is a highly debated field. Despite the proven axillary downstaging occurring after PST, there is still some degree of reluctance in applying sentinel node biopsy (SNB) in the neoadjuvant setting.We performed a retrospective analysis (...) , by molecular subtype 15% (3/20) in Luminal A, 46.4% (45/97) in Luminal B, 90.9% (20/22) in HER2+ and 70.3% (26/37) in triple negative breast tumours.SNB application after PST for breast cancer in node positive patients at presentation is increasing. Pre-operative axillary imaging and tumour biology help identify patients who might be candidates for SNB as a single staging procedure.Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All

2019 European Journal of Surgical Oncology

17. Sentinel Lymph Node Biopsy Pathology and 2-Year Postsurgical Recurrence of Breast Cancer in Kenyan Women Full Text available with Trip Pro

Sentinel Lymph Node Biopsy Pathology and 2-Year Postsurgical Recurrence of Breast Cancer in Kenyan Women The goal of this study was to describe the pathologic findings and early follow-up experience of patients who underwent a sentinel lymph node biopsy (SLNB) at Aga Khan University Hospital (AKUH) between 2008 and 2017.We performed a retrospective analysis of women with breast cancer who underwent an SLNB at AKUH between 2008 and 2017. The SLNB was performed on patients with stage I and stage (...) II breast cancer, and identification of the sentinel lymph node was made by radioactive tracer, blue dye, or both, per availability and surgeon preference. Demographic, surgical, and pathologic data, including immunohistochemistry of the surgical sample for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, were abstracted from the patient records. Follow-up data were available for a subset of patients.Between 2008 and 2017, six surgeons performed SLNBs on 138

2017 Journal of global oncology

18. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer Update Full Text available with Trip Pro

Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer Update Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2016.71.0947 Journal of Clinical Oncology - published online before print December 12 (...) , 2016 PMID: Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update x Gary H. Lyman , x Mark R. Somerfield , x Linda D. Bosserman , x Cheryl L. Perkins , x Donald L. Weaver , and x Armando E. Giuliano Gary H. Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Mark R. Somerfield, American Society of Clinical Oncology, Alexandria, VA; Linda D. Bosserman, City of Hope, Duarte

2016 American Society of Clinical Oncology Guidelines

19. Comparison of the indocyanine green dye method versus the combined method of indigo carmine blue dye with indocyanine green fluorescence imaging for sentinel lymph node biopsy in breast conservative therapy for stage ≤IIA breast cancer. Full Text available with Trip Pro

Comparison of the indocyanine green dye method versus the combined method of indigo carmine blue dye with indocyanine green fluorescence imaging for sentinel lymph node biopsy in breast conservative therapy for stage ≤IIA breast cancer. Fluorescence imaging (FI) is one of the methods to identify sentinel lymph nodes (SLNs). However, the procedure is technically complicated and requires procedural skills, as SLN biopsy must be conducted in dim light conditions. As an improved version (...) of this method, we introduced a combined method (Combined mixed dye and fluorescence; CMF) consisting of indigo carmine blue dye and FI. The direct visualization of SLNs under shadowless surgical light conditions is facilitated by the addition of the blue dye. We compared the SLN detection rates of CMF with that of the indocyanine green (ICG) dye method (ICG-D).A total of 202 patients with stage ≤IIA breast cancer who underwent breast conservative therapy with separate incision from January 2004 to February

2018 BMC Women's Health

20. Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis Full Text available with Trip Pro

Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast (...) of sentinel lymph node biopsy compared with traditional axillary lymph node dissection for staging women with early breast cancer. The authors concluded that sentinel lymph node biopsy was more effective and less costly but differences were modest. The methods used were transparent but the validity of effectiveness data used in the model was unclear. The authors conclusions reflect the uncertainty in the data and seem appropriate. Type of economic evaluation Cost-utility analysis Study objective The aim

2012 NHS Economic Evaluation Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>